Figure 4
From: Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer
Validation of the prognostic CR-based signature in the GSE13507 set. A. Kaplan-Meier survival analysis of BLCA patients between high-risk groups and low-risk groups in GSE13507 set; B. Time-independent receiver operating characteristic (ROC) analysis of risk scores predicting the overall survival in GSE13507 set; C. Distribution of survival status based on the median risk score in GSE13507 set; D. Heatmap showed the differences of 11 chromatin regulators between high and low-risk patients in GSE13507 set